Photo from academic.microsoft.com
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of… Click to show full abstract
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
Keywords:
nephropathy renoprotective;
renoprotective effects;
glp1r agonists;
effects glp1r;
diabetic nephropathy;
agonists sglt2
Journal Title: Nature Reviews Nephrology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Nephrology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!